Enterprise Value
1.661B
Cash
1.059B
Avg Qtr Burn
-76.44M
Short % of Float
22.30%
Insider Ownership
1.90%
Institutional Own.
85.44%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BEAM-101 Details Beta thalessemia, Sickle cell disease | Phase 1/2 Data readout | |
BEAM-201 Details Blood cancer, Cancer, T-cell lymphoma | Phase 1/2 Initiation |